Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis by Valero Telleria, Ana et al.
pharmaceutics
Article
Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial
Activity and Resistance Suppression Evaluation by PK/PD Analysis
Ana Valero 1,2, Alicia Rodríguez-Gascón 1,3 , Arantxa Isla 1,3 , Helena Barrasa 4,5 , Ester del Barrio-Tofiño 6,




Rodríguez-Gascón, A.; Isla, A.;
Barrasa, H.; del Barrio-Tofiño, E.;
Oliver, A.; Canut, A.; Solinís, M.Á.
Pseudomonas aeruginosa Susceptibility
in Spain: Antimicrobial Activity and
Resistance Suppression Evaluation by





and José Martínez Lanao
Received: 27 September 2021
Accepted: 4 November 2021
Published: 8 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy,
Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la
Universidad 7, 01006 Vitoria-Gasteiz, Spain; avalero@fhp.cat (A.V.); alicia.rodriguez@ehu.eus (A.R.-G.);
arantxa.isla@ehu.eus (A.I.)
2 Pharmacy Service, Fundació Sant Hospital, Passeig Joan Brudieu 8, 25700 La Seu d’Urgell, Spain
3 Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006 Vitoria-Gasteiz, Spain
4 Instituto de Investigación Sanitaria Bioaraba, 01006 Vitoria-Gasteiz, Spain; helena.barrasagonzalez@osakidetza.eus
5 Intensive Care Unit, Araba University Hospital, Osakidetza Basque Health Service, 01006 Vitoria-Gasteiz, Spain
6 Microbiology Service, Hospital Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa),
07120 Palma de Mallorca, Spain; ester.delbarrio@ssib.es (E.d.B.-T.); antonio.oliver@ssib.es (A.O.)
7 Microbiology Service, University Hospital of Araba, Osakidetza Basque Health Service, 01006 Vitoria-Gasteiz, Spain
* Correspondence: andres.canutblasco@osakidetza.eus (A.C.); marian.solinis@ehu.eus (M.Á.S.);
Tel.: +34-945-0075-60 (A.C.); +34-945-013-469 (M.Á.S.)
Abstract: Pseudomonas aeruginosa remains one of the major causes of healthcare-associated infection
in Europe; in 2019, 12.5% of invasive isolates of P. aeruginosa in Spain presented combined resistance
to ≥3 antimicrobial groups. The Spanish nationwide survey on P. aeruginosa antimicrobial resistance
mechanisms and molecular epidemiology was published in 2019. Based on the information from this
survey, the objective of this work was to analyze the overall antimicrobial activity of the antipseu-
domonal antibiotics considering pharmacokinetic/pharmacodynamic (PK/PD) analysis. The role of
PK/PD to prevent or minimize resistance emergence was also evaluated. A 10,000-subject Monte
Carlo simulation was executed to calculate the probability of target attainment (PTA) and the cumula-
tive fraction of response (CFR) considering the minimum inhibitory concentration (MIC) distribution
of bacteria isolated in ICU or medical wards, and distinguishing between sample types (respiratory
and non-respiratory). Ceftazidime/avibactam followed by ceftolozane/tazobactam and colistin,
categorized as the Reserve by the Access, Watch, Reserve (AWaRe) classification of the World Health
Organization, were the most active antimicrobials, with differences depending on the admission
service, sample type, and dose regimen. Discrepancies between EUCAST-susceptibility breakpoints
for P. aeruginosa and those estimated by PK/PD analysis were detected. Only standard doses of
ceftazidime/avibactam and ceftolozane/tazobactam provided drug concentrations associated with
resistance suppression.
Keywords: Pseudomonas aeruginosa; pharmacokinetic/pharmacodynamic (PK/PD) analysis; Monte
Carlo simulation; antimicrobial resistance; probability of target attainment (PTA); cumulative fraction
of response (CFR)
1. Introduction
The World Health Organization (WHO) has declared antimicrobial resistance as one of
the top 10 global public health threats facing humanity [1]. The emergence of resistance to
multiple antimicrobial agents in pathogenic bacteria has become a significant public health
concern, as there are few, or even sometimes a complete lack of, effective antimicrobial agents
available for infections caused by these bacteria. This fact is especially relevant considering
that, in the last 10 years, no new group of antibiotics has been marketed in Europe [2].
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P. aeruginosa is an opportunistic pathogen that is difficult to treat and eradicate, because
it has evolved multiple mechanisms of resistance categorized as intrinsic, acquired, or
adaptive [3]. In fact, it has an extraordinary ability to develop resistance to nearly all
antimicrobials available either by chromosomal mutations or by acquisition of localized
genes in transferable elements [4].
P. aeruginosa remains one of the major causes of healthcare-associated infection in
Europe, and according to the EARS-Net report 2019, in Spain, 12.5% of invasive isolates of
P. aeruginosa presented combined resistance to ≥ 3 antimicrobial groups [5]. In the ENVIN-
HELICS national registry 2019 (Spanish National ICU-Acquired Infection Surveillance
Study), P. aeruginosa was the second most frequently isolated microorganism, just behind
Escherichia coli, as a cause of nosocomial infections in intensive care units (ICUs), and
the third most frequent (after E. coli and Staphylococcus aureus) in community-acquired
infections requiring ICU admission [6]. Del Barrio-Tofiño et al. [7] published in 2019
the Spanish nationwide survey on P. aeruginosa antimicrobial resistance mechanisms and
molecular epidemiology. This study showed that up to 26.2% of the isolates were classified
as multidrug-resistant (MDR: non-susceptibility to at least one agent in at least three
antibiotic classes), 17.3% as extensively drug-resistant (XDR: non-susceptibility to at least
one agent in all, but one or two antibiotic classes), and 0.1% as pandrug resistant (PDR:
non-susceptibility to all agents in all antimicrobial categories). ICU isolates were more
frequently MDR/XDR than those from other wards. DTR (difficult-to-treat resistance) is a
novel classifier of antimicrobial co-resistance that integrates the impact of resistance into
antibiotic choices [8]. Recently, the Infectious Diseases Society of America published a
guidance for the treatment of DTR-P. aeruginosa [9].
The optimization of the use of antimicrobial agents is one of the five strategic objectives
included in the global action plan endorsed in 2015 by the World Health Assembly to face
antimicrobial resistance [10]. The major indicator of the effect of the antibiotics (pharmacody-
namics, PD) is the minimum inhibitory concentration (MIC), but antimicrobial optimization
also requires information about the time evolution of the antibiotic concentration in the pa-
tients (pharmacokinetics, PK). Pharmacokinetic/pharmacodynamic (PK/PD) analysis has
been applied in recent years to optimize therapy, with the aim of maximizing the efficacy
and reducing side effects of new and old antibiotics, as well as minimizing the emergence
of resistance [11,12]. Currently, it is clearly established that inadequate exposure to antimi-
crobials can lead to the amplification of resistant subpopulations. The generation of resistant
mutants within a bacterial population is an inevitable event, but it is possible to intervene to
avoid or reduce the amplification of such subpopulation, and thus to preserve the activity of
antimicrobials [13]. Different strategies have been implemented in hospital care to optimize
the antimicrobial dosage regimens [14] and, in this context, PK/PD analysis has become an
essential tool to be included in antimicrobial stewardship programs [15].
Therefore, based on the information of the large-scale Spanish nationwide survey on
P. aeruginosa molecular epidemiology and antimicrobial resistance, the objective of this
work was to analyze the overall antimicrobial activity of the antipseudomonal antibiotics
considering PK/PD criteria. The antimicrobial therapy optimization by PK/PD analysis
was applied separately for ICU and medical ward isolates, as well as distinguishing
between respiratory and non-respiratory isolates, to support the selection of the appropriate
antimicrobial and predicting the dosage regimen with a higher probability of success. A
secondary objective was to evaluate the role of PK/PD analysis to prevent or minimize the
emergence of resistance to these antimicrobials.
2. Materials and Methods
2.1. Antimicrobials and Pharmacokinetic Data
Tables 1 and 2 show the evaluated antimicrobials, their dosage regimens according to
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [16], and the
PK parameters in ICU and medical ward patients, respectively. Population PK parameters
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were obtained from the literature. Prospective studies performed in critically ill and in
medical ward patients with infections were selected.
Table 1. Pharmacokinetic parameters for each antimicrobial agent from published studies among critically ill patients






Time (h) Vd (L) Cl (L/h) Ke (h
−1) Fu References
Amikacin 25–30 mg/kg q 24h 0.5 36.27 ± 8.34 5.58 ± 1.56 [17]
Aztreonam 2 g q 6 h
2
27.20 ± 20.80 9.60 ± 5.00 0.72 [18]3
Cefepime 2 g q 8 h 0.5 21.80 ± 5.10 7.62 ± 1.98 0.85 [19,20]3
Ceftazidime
2 g q 8 h 0.5
18.90 ± 9.00 0.27 ± 0.21 0.80 [21]1 g q 4 h 3
Ceftazidime/
avibactam
2/0.5 g q 8 h 2
34.78 ± 10.49 6.14 ± 3.80 0.90
[22–24]50.81 ± 14.32 11.09 ± 6.78 0.92
Ceftolozane/
tazobactam
1/0.5 g q 8 h
2/1 g q 8 h 1
20.40 ± 3.70 7.20 ± 3.20 0.79
[25,26]32.40 ± 10.00 25.40 ± 9.40 0.70
Ciprofloxacin 400 mg q 8 h 1 13.60 ± 5.80 [27]
Colistin 150 mg q 12 h 0.5 2.92 ± 2.72 [28]
Imipenem 1 g q 6 h 1 28.70 ± 9.70 11.40 ± 3.53 0.80 [29]2
Meropenem 2 g q 8 h 0.5 22.70 ± 3.70 13.60 ± 2.08 0.98 [30]3
Piperacillin/
tazobactam
4/0.5 g q 6 h 0.5 19.40 ± 7.76 13.80 ± 4.77 0.75 [31]4
Tobramycin 6–7 mg/kg q 24 h 0.5 17.50 ± 5.25 0.25 ± 0.01 [32]
Vd: volume of distribution; Cl: total clearance; Ke: elimination rate constant; Fu: unbound fraction.
Table 2. Dosing regimen and pharmacokinetic parameters for each antimicrobial agent from published studies in non-




Time (h) Vd (L) Cl (L/h)
AUC
(mg/L · h) Fu References
Amikacin 25–30 mg/kg q 24 h 0.5 15.80 ± 3.50 5.87 ± 0.98 [33]
Aztreonam 2 g q 6 h
2 0.14 ± 0.04 (L/kg) 4.41 ± 0.63 0.40 [34]3
Cefepime 1 g q 8 h 0.5 0.28 ± 0.25 (L/kg) 7.00 ± 4.30 0.80 [35]2 g q 12 h 3
Ceftazidime 1 g q 8 h
0.5
15.75 ± 1.50 6.96 ± 1.08 0.90 [36]3
Ceftazidime/
avibactam
2/0.5 g q 8 h 2
18.70 ± 1.65 7.53 ± 1.28 0.90 [24,37]25.30 ± 4.43 12.30 ± 1.96 0.92
Ceftolozane/
tazobactam
1/0.5 g q 8 h
2/1 g q 8 h 1
13.50 ± 2,83 4.76 ± 1.13 0.79
[38–40]18.20 ± 4.55 20.51 ± 4.40 0.70
Ciprofloxacin 400 mg q 12 h 1 20.80 ± 5.70 [41]
Colistin 150 mg q 12 h 0.5 2.92 ± 0.10 [42]
Imipenem 500 mg q 6 h 1 16.50 ± 3.75 10.50 ± 1.38 0.90 [43]2
Meropenem 1 g q 8 h 0.5 20.25 ± 3.00 14.40 ± 1.80 0.92 [43]3
Piperacillin/
tazobactam
4/0.5 g q 8 h 0.5 11.25 ± 1.50 10.22 ± 2.12 0.70 [43]4
Tobramycin 6–7 mg/kg q 24 h 0.5 20.50 ± 11.40 5.19 ± 0.91 [44,45]
Vd: volume of distribution; Cl: total clearance; AUC: area under the curve; Fu: unbound fraction.
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2.2. Microbiological Data
Microbiological data (MIC distributions) were extracted from the Spanish nationwide
survey study about P. aeruginosa isolates collected from 51 participating hospitals, covering
all 17 Spanish regions during October 2017 [7], carried out by the GEMARA-SEIMC/REIPI
group [46]. The collection included up to 30 consecutive health care-associated non-duplicated
(one per patient) P. aeruginosa clinical isolates from respiratory, urinary, blood-stream, skin
and soft tissue, and osteo-articular, as well as other sample types, and ICU, medical ward,
surgical ward, emergency room, and other sources were recorded for each isolate.
Isolates were classified according to the admission service (ICU or medical wards) and
according to the sample type (respiratory and non-respiratory). Respiratory samples were
collected from tracheal aspirate, bronchial aspiration, sputum, bronchoalveolar lavage,
pleural fluid, and bronchial brushing in ICU. In medical wards, the origin of these samples
was the same as that from patients from the ICU and nasopharyngeal aspirate and sputum
(from cystic fibrosis patients). Based on the location, 91.5% of isolates were collected
outside the ICU (only 8.5% of isolates were from ICU). Most samples from ICU patients
were from respiratory sources (58.3%); by contrast, most samples collected from medical
ward patients were from non-respiratory sources (69.4%).
Susceptibility was recalculated according to the EUCAST breakpoints 2021 [16]. It is
important to consider that, in 2019, EUCAST changed definitions of susceptibility testing
categories, and intermediate (I-category) was defined as susceptible at increased exposure.
Concerning antipseudomonal antimicrobials included in this study, aztreonam, cefepime,
ceftazidime, ciprofloxacin, imipenem, and piperacillin/tazobactam are included in this
new I-category. The EUCAST breakpoint for imipenem changed from 8 mg/L in 2018 to
4 mg/L in 2021. Table 3 shows the susceptibility rate of P. aeruginosa strains classified by
admission service and sample location.
Table 3. Percentage of P. aeruginosa susceptible strains in 2017, classified by admission service and sample location, according
to the Spanish nationwide survey [7] and applying EUCAST clinical breakpoints [16].
Susceptibility (%)
ICU Medical Ward Patients
Antimicrobial Agent and





Amikacin 91 ** 93 ** 90 ** 92 ** 96 ** 97 **
Aztreonam 70 64 77 87 87 87
Cefepime 67 69 65 80 72 82
Ceftazidime 64 67 60 81 79 83
Ceftazidime/avibactam 85 87 83 95 ** 96 ** 95 **
Ceftolozane/
tazobactam 81 87 73 96 ** 95 ** 96 **
Ciprofloxacin 52 46 60 62 55 65
Colistin 95 ** 96 ** 94 ** 95 ** 96 ** 94 **
Imipenem 55 57 52 75 72 75
Meropenem 71 73 69 80 87 87
Piperacillin/
tazobactam 57 57 58 75 73 76
Tobramycin 74 75 73 84 84 85
** susceptibility ≥90%; underlined and in italics, susceptibility ≥80% and <90%.
Pharmaceutics 2021, 13, 1899 5 of 18
2.3. PK/PD Analysis and Monte Carlo Simulation
Depending on the activity pattern of the antimicrobial, three different PK/PD indices
have been defined as the best descriptors of clinical efficacy [12]: (i) for concentration-
dependent activity antimicrobials, the ratio of the total or free-drug maximum concentration
(Cmax) to the MIC (Cmax/MIC) or the area under the total or free-drug concentration–time
curve, typically over a 24 h period, to the MIC (AUC24h/MIC); (ii) for time-dependent
patterns, the percentage of time the free drug concentration remains above the MIC through-
out the dosage interval (%ƒT>MIC); and (iii) AUC24h/MIC concentration-dependent with
time-dependence antibiotics [11,47].
Table 4 shows the PK/PD indexes and the magnitude of the targets associated with
the success of therapy for each antimicrobial. For time-dependent pattern antimicrobials,
steady-state concentration (Css) > 4 × MIC was selected as the primary endpoint to evaluate
the suitability of the continuous infusion dosage regimens in ICU patients [48].
Table 4. Pharmacokinetic/pharmacodynamics (PK/PD) index and target magnitude for each antimi-
crobial agent.
Antimicrobial Agent PK/PD Target References
Amikacin Cmax/MIC > 10 [49]
Aztreonam %ƒT>MIC > 60 [18]
Cefepime %ƒT>MIC > 70 [50]








%ƒT > 1 mg/L > 20% [25,26]
Ciprofloxacin f AUC24h/MIC > 125 [51]
Colistin f AUC24h/MIC > 25–35 [52]
Imipenem %ƒT>MIC > 40 [12]
Meropenem %ƒT>MIC > 40 [51]
Piperacillin/tazobactam %ƒT>MIC > 50 [41]
Tobramycin Cmax/MIC > 10 [36]
Time-dependent antimicrobials
Continuous infusion Css > 4 × MIC [48]
%ƒT>MIC: Percentage of time that the antimicrobial free serum concentration remained above the MIC;
%f T > 1 mg/L: cumulative percentage over a 24 h period that the free drug concentration exceeded a 1 mg/L
threshold concentration; ƒAUC24h: area under the free drug concentration–time curve over a 24 h period; Cmax:
maximum drug plasma concentration; MIC: minimum inhibitory concentration; Css: steady-state concentration.
PK/PD indices and the defined targets for suppression of the emergence of resistance
are presented in Table 5.
With the defined PK/PD targets, the probability of target attainment (PTA) and the
cumulative fraction of response (CFR) were calculated by Monte Carlo simulation with
Oracle® Crystal Ball Fusion Edition v.11.1.2.3.500 software (Oracle Inc., Redwood City,
CA, USA) and using 10,000 random iterations of the data. Logarithmic transformation
was applied to the mean and the standard deviation of all pharmacokinetic parameters to
normalize their distributions, whereas protein binding was included as a fixed value.
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Table 5. The pharmacokinetic/pharmacodynamic (PK/PD) indices reported to suppress the emer-
gence of antibiotic resistance for P. aeruginosa.
Antimicrobial PK/PD Index PK/PD Index Magnitude References
Total Drug Free Drug
Cefepime Cmin/MIC ≥ 3.8 [53]
Ceftazidime %ƒT>MIC ≥ 100 [54]
Ceftazidime/avibactam %ƒT>MIC ≥ 87 [55]
Ceftolozane/tazobactam %ƒT>MIC ≥ 80 [56]
Piperacillin/tazobactam Cmin/MIC ≥ 5 [57]
Meropenem Cmin/MIC ≥ 3.8 [53]
Imipenem AUC24/MIC = 140 [58]
Ciprofloxacin f AUC24/MIC ≥ 385 [59]
Cmin: minimum concentration; MIC: minimum inhibitory concentration; %ƒT>MIC: percentage of time that the
antimicrobial-free serum concentration remains above the MIC; AUC24h: area under the concentration–time curve
from 0 h to 24 h.
2.3.1. Probability of Target Attainment (PTA) Estimation
PTA is the probability that a specific value of the PK/PD index associated with the
efficacy of the antibiotic is achieved at a certain MIC [12]. PTA was calculated using the
following equations:
• Time-dependent activity antimicrobials;
• IV infusion.




where %ƒT>MIC is the proportion of time that the free serum concentration remains above
the MIC at steady state (%) over a dosage interval, t1 (h) corresponds to the time at which the
free serum concentration reached the MIC during the infusion phase; t2 (h) corresponds to the
post-infusion time at which the free serum concentration equaled the MIC in the elimination
phase; and τ is the dosage interval. The times t1 and t2 were calculated as follows:
t1 =
(MIC − f Cmin,ss)










where Ke is the elimination rate constant.
The minimum and maximum serum concentrations of unbound drug (mg/L) at
steady state, ƒCmin,ss and ƒCmax,ss, respectively, were estimated according to the following
equations using the total clearance (Cl), volume of distribution (Vd), infusion time (ti),
dosage interval (τ), total dose administered (D), and unbound fraction (ƒu):
f Cmin,ss = f Cmax,ss· e−
Cl
Vd−(τ−ti) (4)





Vd ·ti ) · 1
1 − e− ClVd ·
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where AUC24h is the area under the serum concentration–time curve over 24 h.
PTA values (%) were calculated for each dosage regimen for both ICU and medical
ward dose regimens for an MIC range from 0.0125 to 512 mg/L. Considering that the actual
PTA in an individual patient may be significantly different from what would be concluded
from a conventional simulation [60], 95% confidence intervals were calculated as the range
from the 2.5th to the 97.5th percentile of the set of estimated values.
The dosage regimens were considered successful if PTA was ≥90%, whereas a PTA
≥80%, but <90% was associated with moderate probabilities of success [61].
2.3.2. Calculation of the Cumulative Fraction of Response (CFR)
CFR is the expected probability of success of a dosage regimen against bacteria in the
absence of the specific value of MIC, thus the population distribution of MICs is used [12].
It was calculated using Equation (9):
CFR = ∑ni−1 PTAi × Fi (9)
where CFR (%) results from the total sum of the products of the PTA at a certain MIC times the
frequency (Fi) of isolates of microorganism exhibiting that MIC over the range of susceptible
pathogens. The range of MIC concentrations tested for each antimicrobial includes dilutions
below the susceptibility breakpoint; therefore, it is adequate to estimate CFR.
The CMI ranges evaluated for each antimicrobial were as follows: amikacin (2–128 mg/L),
aztreonam (2–56 mg/L), cefepime and ceftazidime (1–128 mg/L), ceftazidime/avibactam and
ceftolozane/tazobactam (0.5–64 mg/L), ciprofloxacin (0.125–32 mg/L), colistin (0.5–16 mg/L),
imipenem (0.5–64 mg/L), meropenem (0.5–128 mg/L), piperacillin/tazobactam (4–512 mg/L),
and tobramycin (0.25–64 mg/L).
The 95% confidence intervals were calculated as the range from the 2.5th to the 97.5th
percentile of the set of estimated values.
A CFR ≥80%, but <90% was associated with moderate probabilities of success,
whereas a CFR ≥90% was considered as optimal against that bacterial population [12].
2.3.3. Calculation of the Joint Probability of PK/PD Target Attainment
Joint PTA, calculated for beta-lactam and beta-lactamase inhibitor combinations, are
defined as the simultaneous attainment of each individual PTA [23]. It was calculated by
determining first if, in each simulated population, the PTA for the beta-lactamase inhibitor is
achieved. If this threshold was met, the joint PTA is considered to be the calculated beta-lactam.
3. Results
Figures 1 and 2 feature the PTA values calculated by Monte Carlo simulation, con-
sidering the EUCAST breakpoints (including susceptible and intermediate categories), at
MIC values ranging from 0.125 mg/L to 512 mg/L for each antimicrobial dosage regimen
recommended in both ICU and medical wards. PTA values collected in the Supporting
Information (Tables S1 and S2) include the 95% confidence interval.
For ICU dosage regimens, PTAs higher than 90% were obtained with ceftazidime/
avibactam, cefepime, ceftazidime, ceftolozane/tazobactam imipenem, meropenem, and
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piperacillin/tazobactam depending on the dose regimen, although, in the case of cefepime,
ceftazidime, and piperacillin/tazobactam, only when they are administered as extended
infusion. PTA values were under 80% for amikacin and aztreonam, covering MICs up to
4 mg/L and 2 mg/L, respectively, far from the clinical breakpoint (16 mg/L). For medical
ward regimen dosages, PTAs higher than 90% were observed for aztreonam, the two
new combinations of cephalosporins with beta-lactamase inhibitor, colistin, imipenem,
meropenem, and piperacillin/tazobactam, if extended infusion (4 h) is considered. All
other antimicrobials showed PTA values under 80% for all dosage regimens evaluated.
Tobramycin administered at 7 mg/kg q 24 h showed a PTA value of 72%, although the 95%
confidence interval ranged from 69% to 84%, that is, including values corresponding to
moderate probabilities of target attainment (>80–90%).
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of P. aeruginosa for each antimicrobial. ICU: intensive care unit; M : medical ward; S: susceptible; I: intermediate category
(susceptible at increased exposure).
Table 6 features the l es obtained, including the 2.5th and 97.5th percentiles,
considering the MIC distribution of the isolates classified by admission service and sample
location. CFR values estimated from the MIC profile of ICU isolates were below 75% for
most antimicrobial regimens, and only ceftazidime/avibactam showed a CFR > 90% (95%),
although, with colistin, it was 89%. Only moderate probabilities of success were obtained
with ceftolozane/tazobactam (both dosage regimens), ceftazidime (dose 1 g q 4 h, both
standard and extended infusion), and meropenem. CFR for amikacin was 71%, despite its
hig susceptibility values (>90%).
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Table 6. Cumulative fraction of response (CFR) calculated for all dosing regimens classified by admission service and




ICU Medical Ward Patients
Amikacin Total Respiratory Non-Respiratory Total Respiratory Non-Respiratory
25 mg/kg q 24 h 71 (68–74) 77 (75–79) 63 (60–66) 92 (91–94) ** 88 (86–90) * 94 (93–96) **
30 mg/kg q 24 h 72 (69–75) 81 (78–84) 67 (64–70) 92 (91–94) ** 90 (88–92) ** 95 (94–97) **
Aztreonam
2 g q 6 h (2 h inf.) 65 (62–69) 62 (59–65) 70 (67–73) 86 (83–87) * 85 (83–87) * 87 (84–89) *
2 g q 6 h (3 h inf.) 69 (66–71) 66 (64–70) 71 (68–74) 86 (84–88) * 85 (83–87) * 87 (85–89) *
Cefepime
1 g q 8 h (0.5 h inf.) 57 (54–60) 51 (48–54) 53 (50–57)
2 g q 12 h (0.5 h inf.) 48 (45–51) 45 (42–48) 46 (43–49)
2 g q 8 h (0.5 h inf.) 68 (71–61) 67 (64–69) 65 (62–68)
1 g q 8 h (3 h inf.) 63 (59–66) 59 (56–62) 65 (62–68)
2 g q 12 h (3 h inf.) 53 (49–55) 53 (51–55) 55 (53–59)
2 g q 8 h (3 h inf.) 77(75–80) 76 (73–78) 73 (70–75)
Ceftazidime
1 g q 4 h (0.5 h inf.) 80 (78–83) * 83(81–86) * 78 (75–81)
1 g q 8 h (0.5 h inf.) 68 (65–70) 63 (60–66) 64 (60–66)
2 g q 8 h (0.5 h inf.) 76 (74–79) 76 (73–79) 72 (69–75)
1 g q 4 h (3 h inf.) 85 (82–87) * 85 (83–87) 81 (78–83) *
1 g q 8 h (3 h inf.) 73 (71–76) 75 (72–77) 74 (72–77)
2 g q 8 h (3 h inf.) 79 (76–82) 81 (79–83) * 77 (74–80)
Ceftazidime/avibactam
2/0.5 g q 8 h (2 h inf.) 95 (94–97) ** 98 (97–99) ** 93 (92–95) ** 97 (96–98) ** 98 (97–98) ** 97 (96–99) **
Ceftolozane/tazobactam
1/0.5 g q 8 h (1 h inf.) 84 (81–86) * 85 (82–87) * 81 (78–83) * 95 (94–96) ** 92 (91–94) ** 96 (95–98) **
2/1 g q 8 h (1 h inf.) 86 (84–88) * 92 (91–94) ** 83 (81–86) * 96 (95–97) ** 95 (94–96) ** 97 (95–98) **
Ciprofloxacin
400 mg q 12 h 53 (50–57) 43 (40–47) 58 (55–61)
400 mg q 8 h 54 (51–57) 48 (45–50) 59 (56–63)
Colistin
150 mg q 12 h 89 (86–90) * 88 (86–90) * 88 (87–90) * 95 (94–96) ** 95 (94–97) ** 94 (93–95) **
Imipenem
500 mg q 6 h (1 h inf.) 75 (72–78) 75 (73–77) 78 (76–80)
1 g q 6 h (1 h inf.) 77 (74–79) 83 (81–85) * 77 (75–80)
500 mg q 6 h (2 h inf.) 77 (75–80) 75 (73–78) 78 (75–80)
1 g q 6 h (2 h inf.) 81 (79–84) * 83 (81–85) * 76 (73–79)
Meropenem
1 g q 8 h (0.5 h inf.) 79 (77–82) 80 (77–82) * 80 (78–84) *
2 g q 8 h (0.5 h inf.) 77 (74–80) 79 (77–82) 73 (71–76)
1 g q 8 h (3 h inf.) 84 (81–86) * 82 (80–84) * 83 (81–86) *
2 g q 8 h (3 h inf.) 82 (79–84) * 86 (84–88) * 77 (75–80)





ICU Medical Ward Patients
Amikacin Total Respiratory Non-Respiratory Total Respiratory Non-Respiratory
Piperacillin/tazobactam
4/0.5 g q 8 h (0.5 h inf.) 51 (48–54) 50 (46–54) 50 (47–53)
4/0.5 g q 6 h (0.5 h inf.) 53 (49–56) 52 (49–56) 55 (52–59)
4/0.5 g q 8 h (4 h inf.) 79 (76–82) 75 (73–78) 76 (74–79)
4/0.5 g q 6 h (4 h inf.) 64 (61–67) 67 (64–70) 68 (64–70)
Tobramycin
6 mg/kg q 24 h 72 (69–75) 72 (69–75) 71 (68–75) 81 (79–84) * 80 (78–83) * 81 (79–83) *
7 mg/kg q 24 h 70 (67–73) 71 (69–74) 72 (69–75) 82 (79–84) * 82 (79–84) * 83 (81–85) *
** susceptibility ≥90%; * susceptibility ≥80% and <90%; inf: infusion time.
Table 7 shows the probability to reach the suppression of the emergence of antimi-
crobial resistance, taking into account the MIC distribution of the isolates against the
studied antimicrobials. For ICU patients, with the dosage regimens used in clinical prac-
tice, no treatment allows to obtain probabilities higher than 90%. Ceftazidime/avibactam
reaches a probability of 89% (87–91%) and the highest dose of ceftolozane/tazobactam
reaches 86% (84–88%). For medical ward patients, values > 90% were reached only with
ceftolozane/tazobactam and ceftazidime/avibactam.
Table 7. Cumulative fraction of response (CFR) calculated for all dosing regimens considering PK/PD




Dosing Regimen ICU Medical Ward Patients
Cefepime
1 g q 8 h (0.5 h inf.) 20 (18–23)
2 g q 12 h (0.5 h inf.) 14 (12–16)
2 g q 8 h (0.5 h inf.) 10 (9–12)
1 g q 8 h (3 h inf.) 19 (17–22)
2 g q 12 h (3 h inf.) 16 (14–19)
2 g q 8 h (3 h inf.) 19 (17–21)
Ceftazidime
1 g q 4 h (0.5 h inf.) 78 (76–81)
1 g q 8 h (0.5 h inf.) 26 (23–29)
2 g q 8 h (0.5 h inf.) 65 (62–68)
1 g q 4 h (3 h inf.) 81 (79–84) *
1 g q 8 h (3 h inf.) 51 (48–54)
2 g q 8 h (3 h inf.) 69 (66–72)
Ceftazidime/avibactam
2/0.5 g q 8 h (2 h inf.) 89 (87–91) * 91 (90–93) **
Ceftolozane/tazobactam
1/0.5 g q 8 h (1 h inf.) 77 (75–80) 96 (95–97) **
2/1 g q 8 h (1 h inf.) 86 (84–88) * 97 (97–98) **




Dosing Regimen ICU Medical Ward Patients
Ciprofloxacin
400 mg q 12 h 0 (0–0)
400 mg q 8 h 36 (33–39)
Imipenem
500 mg q 6 h 0 (0–0)
1 g q 6 h 42 (39–45)
Meropenem
1 g q 8 h (0.5 h inf.) 0 (0–0)
2 g q 8 h (0.5 h inf.) 5 (4–7)
1 g q 8 h (3 h inf.) 1 (0–2)
2 g q 8 h (3 h inf.) 15 (13–18)
Piperacillin/tazobactam
4/0.5 g q 8 h (0.5 h inf.) 0 (0–0)
4/0.5 g q 6 h (0.5 h inf.) 2 (1–3)
4/0.5 g q 8 h (4 h inf.) 0 (0–0)
4/0.5 g q 6 h (4 h inf.) 8 (7–10)
** CFR ≥ 90%; * CFR ≥ 80% and < 90%; inf: infusion time.
4. Discussion
P. aeruginosa is among the antimicrobial-resistant gram-negative bacteria challenging
current health care. The establishment of programs of antimicrobial activity surveillance
integrating local epidemiologic is essential to guide clinicians towards appropriate empiric
treatments. The incorporation of PK/PD analysis into these programs affords a valuable
complementary tool for a rational antimicrobial and dosage regimen selection. The Spanish
nationwide survey on P. aeruginosa antimicrobial resistance mechanisms and molecular
epidemiology [7] showed that the highest susceptibility rates in both ICU and medical
ward isolates were detected for amikacin, ceftazidime/avibactam, ceftolozane/tazobactam,
and colistin and, except for these last three antimicrobials, a high prevalence of XDR pheno-
types and resistance was documented. In this work, the overall antimicrobial activity of the
antipseudomonal antibiotics was assessed by PK/PD analysis to estimate the probability of
success of the treatments, incorporating the variability of the pharmacokinetic parameters
and the bacterial population. Ceftazidime/avibactam, followed by ceftolozane/tazobactam
and colistin, were the most active antimicrobials, with differences depending on the ad-
mission service, sample type, and dose regimen. Furthermore, the new combinations of
cephalosporins with beta-lactamase inhibitors provided drug exposures associated with
resistance suppression at recommended doses.
Standard surveillance indices based on MIC values are insufficient to detect changes in
antimicrobial agents´overall activity, as some less obvious variations in MIC distribution may
result in treatment efficacy loss. In this regard, different studies on P. aeruginosa [40,62,63]
highlight that the susceptibility rates and the probability of treatment success estimated by
the PK/PD analysis are complementary tools that should be considered together to guide
antimicrobial therapy. Our results (Figures 1 and 2) show relevant discrepancies between
EUCAST-susceptibility breakpoints and those estimated by PK/PD analysis, defined as the
highest MIC value at which a high probability of target attainment is obtained (PTA ≥ 90%).
In this sense, the EMA also defends the use of PTA to predict whether a treatment may be
useful against a specific microorganism, and underlines its relevance for the treatment of
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infections caused by multi-resistant bacteria [61]. Besides, in 2019, EUCAST implemented
changes to the definitions of susceptibility testing categories to emphasize the relationship
between breakpoints and exposure of the organism for the agent at the site of infection,
even recommending extended infusions for some time-dependent antimicrobials. As can be
observed in Figures 1 and 2 and Supplementary Tables S1 and S2, prolonged infusions of
time-dependent antimicrobials enhance PTA against non-susceptible P. aeruginosa isolates,
thus being a potential therapeutic option for infections due to multidrug-resistant microor-
ganisms. However, in our study, this fact was relevant only for piperacillin/tazobactam. A
recent systematic review [64] concluded that, prior to the implementation of prolonged infu-
sion of antipseudomonal beta-lactam regimens, institutions should consider its advantage
according to multiple variables including local incidence of P. aeruginosa infections, MIC
distributions, pharmacokinetic variables, and PTA, as well as implementation challenges.
The Spanish nationwide survey [7] also indicated a complex scenario with major
differences in local epidemiology, including carbapenemase production, that need to be
acknowledged in order to guide antimicrobial therapy. The estimation of CFRs allows
estimating the probability of success for a treatment without knowledge of the suscepti-
bility of the specific isolate responsible for the infection, but taking into account the MIC
distribution of a particular institution or hospital wards or regions/countries [11]. Overall,
a lack of concordance between susceptibility and CFR values was detected, especially
relevant in ICU. With the exception of amikacin, discordances in ICU show higher values
of CFR than susceptibility rates. Therefore, taking into account the MIC distribution of
UCI isolates in Spain, PK/PD analysis predicts, for the recommended dose regimens, a
probability of treatment success higher than that expected if only the susceptibility data
are considered. On the contrary, considering the isolates from medical wards, when dis-
crepancies are detected, susceptibility percentages are higher than the CFRs calculated,
which may justify treatment failures when dosing selection is based on the susceptibility
rate without considering the antibiotic exposure. These results emphasize the importance
of taking into account the susceptibility MIC distribution of the isolates of the geographical
area or hospital setting and the PK/PD analysis to support empiric therapy.
Monte Carlo simulations were also performed to calculate CFR in ICU for time-
dependent antimicrobials administered as continuous infusion at the highest doses, except
for ceftazidime/avibactam, with a CFR value of 95% at the recommended dose, and
imipenem due to stability concerns. All antimicrobials evaluated, except for ceftolozane/
tazobactam (CFR 85%), provided low CFR values (< 60%) at the PK/PD endpoint of
Css > 4 × MIC. The low values could be due to the restrictive target selected; however,
this endpoint would allow for maximal bacterial killing and protection against bacterial
regrowth considering that critically ill patients are vulnerable to suboptimal dosage and
represent a source of selection of resistance to antibiotics [52]. These results agree with those
obtained in other studies [65] reporting the target attainment of beta-lactam antibiotics in
critically ill patients.
Regarding sample location, recently, Abuhussain et al. [66] conducted a study on
the in vitro potency of antipseudomonal beta-lactams against blood and respiratory iso-
lates of P. aeruginosa from ICU and non-ICU patients; these authors concluded that the
blood sample isolates were more susceptible. In our study, no relevant differences were
observed in susceptibility and CFR values between respiratory and non-respiratory iso-
lates, although, for ceftolozane/tazobactam, the susceptibility of respiratory ICU strains
was higher than that of non-respiratory ones. In this regard, for ICU isolates, respiratory
and non-respiratory, ceftazidime/avibactam was able to attain CFR > 90%, and a high
dose of ceftolozane/tazobactam, indicated for hospital-acquired pneumonia including
ventilator-associated pneumonia [24], provided CFR > 90% only for respiratory infections.
As a final point, PK/PD analysis based on the MIC distributions of the Spanish na-
tional survey was applied to estimate the probability of the suppression of the emergence
of resistance to the different antimicrobial dosage regimens. Different works have reported
the required antimicrobial PK/PD indices to suppress the emergence of P. aeruginosa an-
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tibiotic resistance [53–59], although no standardized methods are currently established
to determine the antibiotic exposure for the attainment of resistance suppression. In
our study, none of the dosage regimens commonly used in ICU patients were able to
attain high probabilities of resistance suppression, although ceftazidime/avibactam and
ceftolozane/tazobactam 2/1 g q 8 h provide moderate probabilities (>80–90%). These new
antimicrobial combinations were the only ones able to provide concentrations associated
with the suppression of resistance at dosage regimens recommended for medical ward
(CFR > 90%). Different studies have also concluded that the exposure required for resis-
tance suppression is usually much higher than that to assess the treatment efficacy [11,54].
Consequently, to avoid resistance, the use of alternative dosage strategies should be consid-
ered, such as extended or continuous infusions, or the use of some antibiotic combinations
for which in vitro studies have demonstrated a clear advantage [47].
With the aim of emphasizing the importance of antimicrobial appropriate use, support-
ing the development of tools for antibiotic management, and to reduce bacterial resistance,
in 2019, the WHO released the Access, Watch, Reserve (AWaRe) classification [67], which cat-
egorizes the antibiotics into different stewardship groups. All antipseudomonals evaluated
in this study are included in the Watch or Reserve category, except amikacin (Access). Apart
from aztreonam, three other antimicrobials are held in reserve, ceftazidime/avibactam,
ceftolozane/tazobactam, and colistin, which, in this work, were found to be the three most
active against P. aeruginosa in terms of susceptibility and CFR, and only the two combinations
are able to suppress the emergence of resistance at standard doses.
Finally, this study presents some limitations: (i) PK/PD analysis was carried out using
the mean PK parameter and their variability, without considering the possible influence
of covariates on the PK behavior of the drugs; (ii) PK information was extracted from
studies carried out in critically ill patients and in hospital ward patients and available
in the literature; and (iii) many of existing studies determining the exposure required to
suppress the emergence of resistance were conducted in vitro, and we have not found the
PK/PD indices required to suppress specifically the emergence of resistance of P. aeruginosa
for all antimicrobials.
5. Conclusions
Considering the susceptibility rate and PK/PD criteria, the most active antimicrobial
against P. aeruginosa was ceftazidime/avibactam, followed by ceftolozane/tazobactam and
colistin, all of them categorized as Reserve by the AWaRe WHO classification. Notewor-
thy discrepancies between EUCAST-susceptibility breakpoints for P. aeruginosa and those
estimated by PK/PD analysis were observed, as well as a lack of concordance between
P. aeruginosa isolates susceptibility and CFR values. Our results also highlight the impor-
tance of considering the local susceptibility profile, such as the admission service of the
patient or the sample location, as well as the PK/PD analysis to support empiric therapy. In
this sense, prolonged infusions of time-dependent antimicrobials enhance PTA against non-
susceptible P. aeruginosa isolate. Furthermore, antimicrobial stewardship programs need
to consider not only the efficacy, but also the capacity to suppress resistance emergence
to select the proper treatment, in terms of optimal choice of drug and dosage regimen.
In this work, based on PK/PD analysis, only standard doses of ceftazidime/avibactam
and ceftolozane/tazobactam provided drug concentrations associated with resistance sup-
pression, confirming the need to use different dosage regimens or alternative therapeutic
strategies to prevent or minimize resistance emergence.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13111899/s1, Table S1: Probability target attainment (PTA) (%) at each value
of minimum inhibitory concentration (MIC) in ICU patients. Numbers in parenthesis indicate the
2.5th and 97.5th percentiles. The solid vertical lines indicate the intercept with the EUCAST clinical
breakpoints of P aeruginosa. Grey shading indicates PTA > 90%. Table S2: Probability target attainment
(PTA) (%) at each value of minimum inhibitory concentration (MIC) in medical ward patients. Numbers
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in parenthesis indicate the 2.5th and 97.5th percentiles. The solid vertical lines indicate the intercept
with the EUCAST clinical breakpoints of P aeruginosa. Grey shading indicates PTA > 90%.
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